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The Role of Muscle Loading on Bone (Re)modeling at the
Developing Enthesis
Alexander M. Tatara, Justin H. Lipner, Rosalina Das, H. Mike Kim, Nikunj Patel, Eleni Ntouvali,
Matthew J. Silva, Stavros Thomopoulos*
Department of Orthopaedic Surgery, Washington University, St. Louis, Missouri, United States of America

Abstract
Muscle forces are necessary for the development and maintenance of a mineralized skeleton. Removal of loads leads to
malformed bones and impaired musculoskeletal function due to changes in bone (re)modeling. In the current study, the
development of a mineralized junction at the interface between muscle and bone was examined under normal and
impaired loading conditions. Unilateral mouse rotator cuff muscles were paralyzed using botulinum toxin A at birth. Control
groups consisted of contralateral shoulders injected with saline and a separate group of normal mice. It was hypothesized
that muscle unloading would suppress bone formation and enhance bone resorption at the enthesis, and that the
unloading-induced bony defects could be rescued by suppressing osteoclast activity. In order to modulate osteoclast
activity, mice were injected with the bisphosphonate alendronate. Bone formation was measured at the tendon enthesis
using alizarin and calcein fluorescent labeling of bone surfaces followed by quantitative histomorphometry of histologic
sections. Bone volume and architecture was measured using micro computed tomography. Osteoclast surface was
determined via quantitative histomorphometry of tartrate resistant acid phosphatase stained histologic sections. Muscle
unloading resulted in delayed initiation of endochondral ossification at the enthesis, but did not impair bone formation rate.
Unloading led to severe defects in bone volume and trabecular bone architecture. These defects were partially rescued by
suppression of osteoclast activity through alendronate treatment, and the effect of alendronate was dose dependent.
Similarly, bone formation rate was increased with increasing alendronate dose across loading groups. The bony defects
caused by unloading were therefore likely due to maintained high osteoclast activity, which normally decreases from
neonatal through mature timepoints. These results have important implications for the treatment of muscle unloading
conditions such as neonatal brachial plexus palsy, which results in shoulder paralysis at birth and subsequent defects in the
rotator cuff enthesis and humeral head.
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plexus during difficult childbirth and affects up to 1 in 250 infants
[12,13,14]. During post-natal development of the shoulder in
normal loading conditions, high osteoclast numbers were seen at
the tendon enthesis, presumably due to the high rate of bone
formation [5]. Osteoclast numbers decreased steadily with
increasing post-natal age. However, in the absence of muscle
load, osteoclast numbers remained elevated, possibly maintaining
high levels of resorption and preventing mineral accumulation in
the developing enthesis and adjacent bone. These defects in bone
(re)modeling led to dramatic impairment of enthesis biomechanics
[10,11].
Skeletal disuse in mature animals leads to both diminished bone
formation and elevated bone resorption [15]. Our previous results
in the developing enthesis implied that defects from paralysis were
partly caused by increased resorption; however, bone formation
was not measured. Our observations therefore led to the question:
were the unloading-induced developmental defects (e.g., bony
architecture, mineralization, enthesis biomechanics) due to suppressed bone formation, elevated bone resorption, or both? More
generally, were these defects due to defective bone modeling

Introduction
The development of a functional musculoskeletal system
requires muscle forces [1,2,3,4]. It is well established that loading
regulates the shape and density of developing bones and the size
and force-generating capacity of developing muscles. The absence
of muscle loads during fetal development retards mineralization
and leads to malformed bone [3]. Similarly, the growth and
development of mineralized tissues is significantly impaired if
muscle load is removed post-natally [5,6,7]. However, little is
known about the force-mediated regulation of the developing
tendon-to-bone attachment (the ‘‘enthesis’’), despite its critical role
in the transfer of muscle forces to bone for subsequent joint motion
[8,9].
We previously showed in a mouse animal model that shoulder
paralysis at birth leads to bony and soft tissue defects by 28 days
post-natally, including impaired bony architecture and decreased
enthesis mechanical properties [5,6,7,10,11]. The bone- and jointlevel deficiencies closely mimicked the clinical condition neonatal
brachial plexus palsy, which results from injury to the brachial
PLOS ONE | www.plosone.org
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(shaping of bone where resorption and formation are uncoupled),
remodeling (coupled action of bone resorption and formation on
the same bone surface), or both? To explore these questions,
muscle load was removed in the current study using muscle
paralysis at birth; osteoclast activity was modulated using
bisphosphonate treatment; and bone formation was measured
using fluorescent labeling of bone surfaces. We hypothesized that
unloading via muscle paralysis would suppress bone formation and
enhance bone resorption at the enthesis, and that the bony defects
could be rescued by suppressing osteoclast activity. Our results
indicated that muscle unloading does not impair bone formation
rate. Rather, it delays the initiation of endochondral ossification.
Suppression of osteoclast activity partially rescued the bony defects
caused by muscle unloading, implicating osteoclast activity as one
cause of impaired enthesis development.

administered weekly through intraperitoneal injections to mice
[16]. Four doses (no dose = 0 mg/kg/week, low dose = 0.125 mg/
kg/week, medium dose = 1 mg/kg/week, and high dose = 2 mg/
kg/week alendronate in PBS) were examined in Normal and
Botox mice (N = 10 for the no dose/Normal group, N = 13–17 per
dose for all other groups). At P28, 5–7 mice from each group were
sacrificed and analyzed for osteoclast surface by quantitative
histomorphometry, and bone volume, bone architecture, and
muscle volume by micro computed tomography (mCT), as
described below. All other mice were given intraperitoneal
injections of calcein green at P25 and intraperitoneal injections
of alizarin red at P31 (i.e., 3 days before and 3 days after P28). At
P35, the mice were sacrificed.

Sample Preparation and Measurement
Humerus-enthesis-muscle samples were dissected, fixed in 10%
formalin, and dehydrated to 70% ethanol. P28 samples allocated
to bone morphometry and TRAP staining were scanned in air by
mCT (mCT 40; Scanco Medical, Basserdorf, Switzerland; 55 kV,
145 mA, 20 mm voxel, 99 msec integration, 250 projections) at
room temperature as described previously [17]. Briefly, supraspinatus muscle volume was measured from the most medial end of
the scapular origin to the insertion on the humeral head. The
volume of bone from the distal end to the anatomical neck of the
superior end of the humeral head was measured for mineralized
bone. This resulted in a region of interest encompassing the
mineralized tissue at the enthesis and the trabecular bone directly
adjacent to the enthesis up to the growth plate. The trabecular
thickness, number, and separation were measured to evaluate the
bone architecture. To determine trabecular parameters, the
endosteal margin of the humeral head was defined using hand
drawn contours followed by thresholding to separate bone from
background (sigma = 0, support = 0, lower/upper threshold = 270/1000 = 332 mg HA/cm3, peel iteration = 4). Standard
outcomes included trabecular bone volume per tissue volume
(BV/TV), trabecular number (Tb.N), thickness (Tb.Th), separation (Tb.Sp) and connectivity density (Conn.D).
After mCT scanning, specimens were paraffin embedded,
sectioned at 5 mm, and stained for tartrate resistant acid
phosphatase (TRAP). Specifically, slides were first incubated in a
solution of sodium acetate, L-(+) tartaric acid, glacial acetic acid,
naphthol AS-BI phosphate, ethylene glycol monoethyl ether, and
distilled water for 45 min at 37uC. Slides were then incubated in a
solution of sodium acetate, L-(+) tartaric acid, glacial acetic acid,
sodium nitrite, pararosaniline chloride, 2N hydrochloric acid, and
distilled water for 5 min at 37uC. Slides were then rinsed in water,
counterstained with haematoxylin, dehydrated through graded
alcohols, cleared with xylenes, and coverslipped. One randomly
chosen section per specimen was analyzed by a single user (NP)
with bright-field microscopy and Bioquant Osteo II software
(Bioquant) for analysis of osteoclast surface on the bone surfaces
adjacent to the enthesis at 16x objective magnification.
Samples allocated to bone formation histomorphometry were
fully dehydrated and embedded in polymethylmethacrylate
(Sigma). Two to three sections of thickness 100 mm were cut from
each sample using a saw microtome (Leica Microsystems, SP
1600) and adhered onto glass slides. The sections were imaged
using an inverted microscope with a 100 W mercury-halogen light
under 10x objective (DP-30, Olympus). The calcein green marker
was captured under a fluorescein isothiocyanate (FITC) filter and
the alizarin red marker was captured using a tetramethylrhodamine isothiocyanate (TRITC) filter. The images were merged with
Olympus software. A bright field image was taken for visualization
of total bone surface. The calcein and alizarin-labeled bone

Materials and Methods
Ethics Statement
The animal procedures and care used in this study were
approved by the institutional Animal Studies Committee at
Washington University (Approval Number: 20130034A3) and
carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National
Institutes of Health.

Animal Model
In order to remove muscle loading across the shoulder during
post-natal development, the left supraspinatus muscles (‘‘Botox’’
group) of neonatal CD-1 mice were injected with 10 mL of 0.2 U
of botulinum toxin A (BOTOX, Allergen, Inc.) (Figure 1) [5,6,7].
The right supraspinatus muscles received saline injections (‘‘Saline’’ group) and served as contralateral controls. Paralysis was
maintained from birth through sacrifice. The injections were
started at day 1 after birth and repeated twice a week to maintain
paralysis through P28. From P28 through 56, injections were
repeated once a week to maintain paralysis. Previous studies
established an effective dose of 0.05 U per gram body weight,
delivered in 10 mL volume with a 30 gauge needle intramuscularly
into the supraspinatus muscle. A separate group of animals was
allowed to develop without saline or botulinum toxin injections
(‘‘Normal’’ group).

Bone Formation
In order to examine the effect of unloading on bone formation
at the enthesis during development, mice were separated into three
time points (post-natal days P14, P28, and P56). Botox/Saline
mice (n = 8–10) and Normal mice (n = 8–11) were examined at
each timepoint. Bone formation was determined based on
injections of labels before and after these timepoints of interest.
In this manner, the measurement of changes between the two
fluorescent labels described cumulative bone formation centered
around the timepoint of interest. Mice were given intraperitoneal
injections of calcein green (5 mg/kg, Sigma-Aldrich) and alizarincomplexone (30 mg/kg, Sigma) 3 days before and 3 days after the
given time point, respectively (Figure 2). 7 days after the given time
point, the animals were sacrificed. Incorporation of the two labels
could then be used to study bone formation a timepoints centered
around P14 (i.e., P11–P17), P28, (i.e., P25–P31), and P56 (i.e.,
P53–P59).

Inhibition of Osteoclast Activity
To clarify the role of osteoclasts in unloading-induced bone
resorption, the bisphosphonate alendronate (Sigma-Aldrich) was
PLOS ONE | www.plosone.org
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Figure 1. The study design consisted of Botox, Saline, and Normal groups treated with varying doses of alendronate and examined
at three post-natal (P) timepoints.
doi:10.1371/journal.pone.0097375.g001

surfaces were analyzed by a single user (AT) with Bioquant Osteo
II software. Analyses were performed for the enthesis and for the
trabecular bone adjacent to the enthesis (Figure 2). The values
measured were averaged between sections to obtain single-labeled
bone surface (sLS/BS), double-labeled bone surface (dLS/BS),
mineralizing surface per bone surface (MS/BS), mineral apposition rate (MAR) and bone formation rate (BFR/BS) for each
sample. MAR and BFR were only computed when there were
double-labels [18]. A result of ‘‘n.d.’’ (‘‘no data’’) is indicated when
an outcome was not computable.

Results
The Effect of Muscle Unloading on Bone Formation at the
Developing Enthesis and Adjacent Trabecular Bone
Bone formation rate and mineralizing surface/bone surface at
the enthesis was highest at P28 (Figure 3; Tables S1–S2 in file S1).
During post-natal shoulder development, different fluorochrome
labeling patterns were seen across time points and loading groups
at the tendon enthesis. At P14, each specimen in the Saline and
Normal groups showed only the second (red alizarin) label. This
implies that mineralization began after the calcein was delivered
(P11) but before the alizarin was delivered (P17). By contrast, only
1 specimen out of 18 in the Botox group showed any label at all at
P14, signifying that mineralization was delayed at least past P17 in
this group. At P28, all groups showed bands of calcein and
alizarin. Importantly, muscle load did not affect bone formation
outcomes at this timepoint. The mineral apposition rate was ,2x
higher and the bone formation rate was ,5x higher in the enthesis
compared to the trabecular bone adjacent to the enthesis (Figure 3;
Tables S1–S2 in file S1). At P56, bands were rarely seen in any
group (calcein bands were seen in 2 out of 8 samples in the normal
group, 0 out of 9 samples in the saline group, and 0 out of 9
samples in the botox group). The lack of fluorophore update was
likely due to the timing of the injections relative to the slow bone
formation rates of this relatively mature timepoint.

Statistics
Botox and Saline groups were compared using paired t-tests.
Botox and Saline were compared to Normal and across time using
an analyses of variance followed by a Fisher’s least squares
difference post-hoc test. Significance was set at p,0.05.

The Effect of Alendronate on the Unloaded Developing
Enthesis and Adjacent Trabecular Bone
Because the histomorphometry results across time (Figure 3)
revealed that the tendon enthesis only absorbed both fluorochrome labels at P28, this time point was chosen to study the
effects of alendronate. When examining the bone at the
supraspinatus enthesis and the adjacent trabeculae, alendronate
increased bone volume and trabecular number in a dosedependent manner and reduced differences between the Normal
and Botox groups (Figure 4; Figure S1 and Table S3 in file S1). It
also increased connective density at medium and high doses.
However, none of the alendronate dosages were able to completely

Figure 2. Alizarin (blue arrows) and calcein (yellow arrows)
labels at the supraspinatus enthesis for representative Botox
and Saline sections at P28. The dotted lines extending to the left in
each panel indicate the approximate location of the supraspinatus
tendon (T). Trabecular bone and the epiphysis of the humeral head can
be seen to the right of the entheses (B).
doi:10.1371/journal.pone.0097375.g002
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Figure 3. Bone formation histomorphometry at the developing enthesis. MS/BS was significantly lower in the Botox group compared to the
Saline and Normal groups at P14 (*p,0.05). There was a significant increase in MS/BS from P14 to P28 followed by a significant decrease from P28 to
P56.
doi:10.1371/journal.pone.0097375.g003

treatment with the bisphosphonate alendronate partially rescued
the bone phenotype resulting from muscle unloading.
We previously described the mineralization process at the
developing rotator cuff tendon enthesis [19]. The transitional
tissue between tendon and bone was examined from P7 through
P56 using a variety of microscopic and spectroscopic techniques.
Mineralizing cartilage originating in the secondary center of
ossification of the humeral head epiphysis was evident at P7 and
reached the tendon interface by P14. A mineral gradient was
observed that spanned the length of one or two hypertrophic
chondrocytes at the developing enthesis. P14 was also a critical
timepoint in the current study; at this timepoint, a clear decrease
in enthesis mineralizing surface was evident in the unloaded
groups compared to the loaded groups. As the cells that form this
mineralization front during this time frame are hypertrophic
chondrocytes, not osteoblasts, we conclude that unloading affected
chondrocyte hypertrophy and not osteoblast-mediated bone
formation. In a previous study, we observed that hypertrophic
chondrocytes remained at the enthesis through P21 in unloaded
specimens whereas loaded controls no longer had hypertrophic
chondrocytes after P14 [5]. Others have also demonstrated that
mechanical load influences endochondral ossification [1,2,3,4,20].
It is possible that removing load delays hypertrophy and/or the
migration of the mineralization front from the center of the
humeral head to the tendon attachment. This is further supported
by the lack of differences in bone formation rate (a measure
primarily of osteoblast activity) at a later timepoint between loaded
and unloaded tissues.
Bone formation of the trabeculae adjacent to the enthesis was
similar to that of the enthesis. Although bone formation rates in
the humeral head were unaffected by removal of load during postnatal growth, dramatic differences were noted in mineralizing
surface and in accumulation of mineral. As with mineralization at
the enthesis, these effects were likely due to a delay in the initiation
of endochondral ossification (i.e., chondrocyte hypertrophy) and in
high osteoclast activity. Previously, we showed that removal of
load in the early post-natal period results in persistence of high
osteoclast lined bony surfaces, whereas loaded tissues show a
significant decline in osteoclast numbers over time [5]. In support
of this, the current study showed that suppression of osteoclast
activity via bisphosphonate treatment can partially rescue the bony
defects caused by muscle unloading. Alendronate treatment led to
increases in bone volume and connective density and in a recovery
of trabecular architecture towards normal. These effects were

return the unloaded tissues back to normal (Figure 4; Figure S1
and Table S3 in file S1). As expected, muscle volume was
decreased due to paralysis and unaffected by alendronate
(Figure 5). Alendronate increased osteoclast surface in a statistically significant, dose-dependent manner (Figure 5; Figure S2 in
file S1). Many of the osteoclasts in the bones treated with medium
and high doses of alendronate appeared abnormal (Figure 5).
These cells were hypernucleated, lacked a lysosome zone, had
pyknotic nuclei, did not show nuclear polarization away from the
bone, and were detached from the underlying bone, suggesting
abnormal function.
At the tendon enthesis in normal animals, alendronate at its
highest dose increased MAR, MS/BS, and BFR/BS at the
enthesis and in the trabecular bone directly adjacent to the
enthesis (Figure 6; Tables S4–S5 in file S1). However, in both the
saline and botox specimens, alendronate had a biphasic effect in
which it increased mineral apposition rate and bone formation
rate at the medium dose but not at the high dose. Alendronate
increased the mineralizing surface to total bone surface ratio
equally regardless of dose. There was no significant effect of
alendronate on mineral apposition rate of the trabecular bone at
P28. In general, there was a trend for increasing dose to increase
bone formation rate and mineralizing surface percentage. There
were no statistically significant results across loading groups. Bone
histomorphometry measures at the enthesis and adjacent bone
were similar when comparing normal, saline, and botox for a
particular alendronate dose (Figure 6; Tables S4–S5 in file S1).

Discussion
The current study demonstrated that muscle loading plays an
important role in the formation of a mineralized enthesis.
Although muscle unloading did not significantly affect measurements such as bone formation rate and mineral apposition rate,
muscle unloading did delay the initiation of the mineralizing front.
This result implies that loading influences only the initial
deposition of mineral at the enthesis, a process which is driven
by endochondral ossification [19]. Similar bone formation rates
were seen for loaded and unloaded tissues at later timepoints,
suggesting that the differences in bone volume and trabecular
architecture between the two groups were due to delayed
accumulation of mineral and increased osteoclast activity, rather
than decreased osteoblast activity. In support of this conclusion,
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Figure 4. The effect of alendronate on bone architecture at P28 (*p,0.05). Alendronate dose and group (Botox vs. Saline vs. Normal)
significantly affected BV/TV, connectivity density, Tb.N, and Tb.Sp. At the highest dose of alendronate, Botox was significantly different than Normal
for BV/TV and Tb.Sp. Note that results for animals without alendronate treatment have been published previously [5].
doi:10.1371/journal.pone.0097375.g004

alendronate treatment in the current study demonstrated similar
morphologies.
Alendronate did not have an effect on bone formation
properties in the trabecular bone across doses or loading regimes.
However, at the enthesis in normal animals, alendronate at its
highest dose increased mineral apposition rate, bone formation
rate, and the mineralizing surface to total bone surface ratio. In
both the Saline and Botox specimens, alendronate had a biphasic
effect in which it increased mineral apposition rate and bone
formation rate at the medium dose but not at the high dose. In
contrast, it was previously reported that bisphosphonates can
suppress osteoblast activity directly and through inhibition of their
crosstalk with osteoclasts, including in unloading conditions
[25,26]. Alendronate may have led to increased available surface
for mineralization by allowing osteoblasts access to surfaces that
would otherwise have been occupied by Howship’s lacunae.
Alternatively, bisphosphonates can also affect bone by directly
preventing osteoblast and osteocyte apoptosis [27,28,29]. This
effect is independent from its effect on osteoclasts and is mediated
through connexin 43. It is unclear if alendronate directly
influenced osteoblasts and osteocytes in the current study. Finally,
it is also possible that there was a direct effect of alendronate on
hypertrophic chondrocytes driving endochondral ossification at
the tendon enthesis.

dose-dependent, although complete restoration of normal properties was not achieved, even at the highest dose.
Treatment with alendronate led to increases in osteoclast
surface in all groups in a dose dependent manner (Figure 5). This
outcome appears contradictory to the observed increases in bone
volume and the improvements in trabecular architecture in
alendronate treated animals. Previously, it was believed that
alendronate promoted apoptosis in osteoclasts and hence decreased their numbers [21,22]. Decreased osteoclast numbers
subsequently led to decreased resorption and increased bone
mineral density. Recent reports, however, have demonstrated that
apoptosis is not required for alendronate to effectively inhibit
resorption [23]. Furthermore, using bone biopsies from a cohort of
healthy post-menopausal women, it was demonstrated that
treatment with alendronate for long periods of time is associated
with increases in the number of osteoclasts [24]. Normal osteoclasts
demonstrate tight cell-bone interfaces, lysosome-rich cytoplasm,
and contain multiple nuclei polarized away from the bone.
Osteoclasts in alendronate treated bones included giant hypernucleated cells lacking a lysosome zone and detached from the
underlying bone, with pyknotic nuclei that were not polarized
away from the bone. The authors suggested that these osteoclasts
resorb bone poorly, if at all. The osteoclasts associated with
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Figure 5. The effects of alendronate on muscle volume and osteoclasts. (A) There was no significant effect of alendronate on muscle
volume at P28. Muscle volume was significantly reduced in the Botox group compared to the Saline and Normal groups. (B) Alendronate dose and
group (Botox vs. Saline vs. Normal) significantly affected osteoclast surface at P28. The effect of alendronate was most pronounced in the Botox
group (*p,0.05). (C–D) High magnification views of osteoclasts (stained in red) in the (C) Normal group with a low dose any of alendronate and (D)
Botox group with a high dose of alendronate. Osteoclasts in the bones treated with high doses of alendronate were hypernucleated (white
arrowheads) and were detached from the underlying bone (black arrows), suggesting abnormal function (100x objective, TRAP stain, scale
bar = 20 mm).
doi:10.1371/journal.pone.0097375.g005

In the current study, both modeling and remodeling were
considered due to the uncertainty associated with the mineralization process at the developing enthesis. Bone modeling shapes the

bone during growth and, in some cases, during adaptation to
changes in mechanical loading [30]. Resorption and formation are
uncoupled during bone modeling. Bone remodeling, on the other

Figure 6. The effect of alendronate on bone formation histomorphometry at P28. There was a significant effect of alendronate on BFR/BS
and MS/BS (*p,0.05).
doi:10.1371/journal.pone.0097375.g006
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previously reported mCT outcomes and osteoclast histomorphometry results for Botox, Saline, and Normal groups at P14, P28, and
P56 (without alendronate treatment) [5]. Although direct statistical
comparisons cannot be made use the previously published data,
collected using slightly different techniques, the trends between
groups in the previous study are consistent with the current study,
especially at the lowest alendronate dose. Furthermore, the bone
formation assays in the current study included a group that did not
receive alendronate.
In summary, this study demonstrated that bone (re)modeling at
the developing enthesis requires muscle forces. Using a mouse
animal model of shoulder paralysis that mimics neonatal brachial
plexus palsy, we determined that the developmental bony defects
that result from muscle unloading are due primarily to elevated
bone resorption, and not suppressed bone formation. Specifically,
when suppressing osteoclast activity at the highest dose of
alendronate, treated shoulders achieved 82% of normal BV/TV,
104% of normal connectivity density, 94% of normal trabecular
number, and 88% of normal trabecular spacing (note that
comparisons are made between groups for a particular dose to
separate the effects of alendronate on normal growth from the
effects of alendronate on botox-induced defects). Initiation of
endochondral ossification in the developing humeral head was
delayed in the absence of loading and suppression of osteoclast
activity partially rescued the bony defects caused by muscle
unloading. These results have important implications for the
treatment of conditions such as neonatal brachial plexus palsy, a
condition that results in shoulder paralysis at birth and subsequent
bony defects in the humeral head.

hand, requires the coupled actions of bone resorption and
formation on the same bone surface [30,31]. In our previous
study, we showed that the unloading-induced bone defects were
likely osteoclast mediated, implying a remodeling process [5].
However, the results from the current study imply that mineralization at the enthesis is a modeling event, with few (if any)
osteoclasts observed (Figure S2 in file S1). This is in contrast to the
bone surfaces adjacent to the enthesis, where osteoclast activity
was high. The effects and mechanisms of action of unloading and
alendronate may therefore differ substantially between the
entheses and the adjacent trabecular bone.
There were several limitations to the current study. First,
although osteoclasts clearly played a dominant role in the
unloading-induced defects at the developing enthesis, the mechanisms of bony defect formation remain unclear. Outcomes in the
current study included quantification of bone formation and bony
architecture, but did not include functional assays such as
biomechanics. In addition, osteoclast activity was not directly
measured (e.g., using serum markers) and osteoblast numbers were
not determined. Also, while osteoclast activity was modulated
using alendronate, osteoblast activity was not manipulated (e.g.,
using parathyroid hormone). A second limitation relates to our
interpretation of missing label in young and unloaded animals.
The lack of label could be due to delayed bone formation or
remodeling of the incorporated label into new (unlabeled) bone.
However, as the enthesis consists of unmineralized endochondral
tissue at timepoints prior to P14, it is unlikely that calcein was
incorporated and then rapidly remodeled in that time frame.
Similarly, based on lower bone mineral in the unloaded groups, it
is similarly unlikely that a calcein label was incorporated and then
rapidly remodeled in those groups. A third limitation is the use of
the saline injected contralateral shoulder as a control. As seen in
our previous studies, there was often a significant change in this
shoulder compared to normal shoulders [5,6,11]. This is attributed
to behavioral changes in mice that have one paralyzed shoulder
and not due to systemic toxic effects of the botulinum toxin, as
neonatal neurotomy leads to similar developmental defects as
chemical denervation [7]. Importantly, in the current study
paralyzed shoulders were also compared to normal shoulders
from a separate set of mice. A fourth limitation is the use of
historical controls to draw conclusions for some outcomes. We

Supporting Information
File S1 Figures S1–S2 and Tables S1–S5 can be found in
the file S1.
(DOCX)
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